공고 • May 28
Aurora Spine Corporation to Report Q1, 2026 Results on May 28, 2026 Aurora Spine Corporation announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on May 28, 2026 공고 • Apr 23
Aurora Spine Corporation to Report Fiscal Year 2025 Results on Apr 29, 2026 Aurora Spine Corporation announced that they will report fiscal year 2025 results at 4:00 PM, US Eastern Standard Time on Apr 29, 2026 공고 • Apr 15
Aurora Spine Corporation, Annual General Meeting, Jun 17, 2026 Aurora Spine Corporation, Annual General Meeting, Jun 17, 2026. 공고 • Oct 28
Aurora Spine Corporation Launches New Biologics Portfolio Aurora Spine Corporation announced the launch of Aurora Biologics, a new division dedicated to advancing spinal fusion success through best-in-class biologic innovation. The establishment of Aurora Biologics creates seamless synergy across Aurora's growing spine ecosystem--including its renowned interspinous, lumbar, and sacroiliac fusion systems such as ZIP™?, Hydra A.E.R.O.™?, DEXA™?, and SiLO™? portfolios. These mechanical and regenerative technologies now converge within one integrated platform designed to enhance patient outcomes, improve surgical efficiency, and promote long-term fusion integrity. Comprehensive Biologic Solutions: Aurora Biologics launches with a complete suite of allograft solutions, including: TURBO FUSE™? Fiber Putty - a bone graft substitute composed of demineralized bone fibers that increase surface area and promote cellular attachment. OSTEO GRAFT™? DBM Putty - a demineralized cortical bone graft with a cohesive, moldable consistency to support bone formation without synthetic carriers. OSTEO BRIDGE™? Sponge Strips - a sponge-like bone graft substitute that conforms to patient anatomy and fills bone voids to support structural regeneration. Each biologic is formulated from 100% allograft bone, free of synthetic carriers, delivering natural osteoconductive and osteoinductive properties for predictable, high-quality bone growth. Fully moldable and cohesive, these materials are designed to fill bony defects or augment fusion sites, providing a natural biologic scaffold for bone regeneration. Engineered to work synergistically with Aurora's implant technologies, the Aurora Biologics line creates a comprehensive, biologically active fusion environment that optimizes outcomes for both patients and surgeons. 공고 • Sep 18
Aurora Spine Corporation Announces Launch of its DEXA-L™? Anterior Lumbar Interbody Fusion Device Aurora Spine Corporation announced the official launch of its DEXA-L Anterior Lumbar Interbody Fusion Device, with the product being implanted in recent initial surgeries. DEXA-L is part of Aurora's patented DEXA Technology Platform, which is a series of products that are the world's first bone density matched implants. The DEXA-L, part of the DEXA Technology Platform, is a stand-alone device for anterior lumbar interbody fusion (ALIF) procedures and is the first of its kind in the world. It is the first spinal implant that is a bone-mimicking™? structural implant helping doctors match the implant to the patient's bone density and quality. Dr. Daniel Barba of San Diego, CA was the first surgeon to use the DEXA-L™? Stand Alone ALIF System in the United States. Dr. Barba stated "Each of my patients are unique. Now I can use a Stand-Alone ALIF cage tailored specifically to their needs. This novel technology allows me to match the modulus of the cage to the bone density of each of my patients. This has enabled me to expand my indications for lumbar fusion within patients that would normally not be a good candidate due to their poor bone quality. The DEXA- L Stand Alone ALIF system, promoting bone density matched DEXA™? Technology, marks another landmark advancement for spinal surgery from Aurora Spine. The company are excited to introduce another procedural solution that accommodates not only standard spine patients but the most challenging patients who are also in need of care. Patient specific options for spine surgery have been advancing over the last several years but not matching a patient's bone density was a glaring need for a significant number of patients. The CDC estimates that almost half of the US population over 50 years of age have low bone mass. This equates to millions of patients that need an implant that matches their bone density when having spine surgery. The DEXA- Ltd. Stand Alone ALIF System now allows surgeons the opportunity to treat patients who have osteopenia or osteoporosis, as well as those who have normal bone density but still need surgery. The days of not matching an implant modulus to the patient are behind the company. 공고 • Jul 09
Aurora Spine Corporation Announces Initial Surgeries Using its Aero Lumbar Fusion System Aurora Spine Corporation announced initial surgeries using Aurora Spine's newest product, the AERO Lumbar Fusion System, have commenced. The minimally invasive procedures using the AERO were conducted by two different surgeons, one ortho surgeon and one interventionalist. The initial surgeries performed were procedures done on the lumbar part of the spine. The AERO MIS Lumbar Fusion System is a novel, patent-pending device designed to provide a minimally invasive solution for patients suffering from facet joint-related pain or instability. Cleared for use from spinal levels C2 to S1 (inclusive), the system can be used as a stand-alone facet fusion procedure or as an adjunct to larger spinal fusion surgeries. Engineered for earlier use in the continuum of care, AERO is ideal for patients experiencing mechanical back pain, minor instability, or degenerative joint disease who have not responded to conservative therapies. The system incorporates intuitive instrumentation and implant technology designed to promote bone fusion while minimizing soft tissue disruption--aligning with Aurora Spine's commitment to advancing patient-first, surgeon-friendly innovations. 공고 • Jun 18
Aurora Spine Corporation Announces the Upcoming Launch of DEXA-L™, A Standalone Anterior Lumbar Interbody Fusion (ALIF) System Built on the Same Award-Winning DEXA Platform Aurora Spine Corporation announced the upcoming fourth quarter 2025 launch of DEXA-L™, a standalone Anterior Lumbar Interbody Fusion (ALIF) system built on the same award-winning DEXA platform. Like DEXA-C™, the DEXA-L™ implant is designed to address the challenges of spinal fusion in patients with varying bone densities — especially those with osteoporosis. For decades, spinal implants were primarily developed for patients with healthy bone stock. However, these implants have demonstrated reduced performance in patients with low bone density, where traditional designs may lack sufficient bone-implant contact and fail to achieve long-term fixation. DEXA Technology™ directly addresses this clinical gap, offering a smart, density-matched solution for today’s diverse patient population. 공고 • May 20
Aurora Spine Corporation to Report Q1, 2025 Results on May 22, 2025 Aurora Spine Corporation announced that they will report Q1, 2025 results Pre-Market on May 22, 2025 공고 • Apr 24
Aurora Spine Corporation to Report Q4, 2024 Results on Apr 28, 2025 Aurora Spine Corporation announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Apr 28, 2025 공고 • Apr 02
Aurora Spine Corporation Announces Publication of Biomechanical Study Demonstrating Superiority of SiLO TFX™? Sacroiliac Joint Fusion System Aurora Spine Corporation announced the publication of a new clinical study titled "Fixation of the Sacroiliac Joint: A Cadaver-Based Concurrent-Controlled Biomechanical Comparison of Posterior Interposition and Posterolateral Transosseous Techniques" in the journal Neurospine. The study evaluates the biomechanical performance of Aurora Spine's SiLO TFX™? MIS Sacroiliac Joint Fixation System compared to traditional posterolateral transosseous techniques. The SiLO TFX™? system is a minimally invasive solution designed for sacroiliac joint fusion, addressing conditions such as sacroiliac joint disruptions and degenerative sacroiliitis. The system includes a Transfixing-Cone, an ilium screw, a sacrum screw, and associated instrumentation, engineered to transfix the sacrum and ilium, thereby providing stability conducive to bony fusion. The SiLO TFX system is designed in accordance with the AO Principles of Fusion--providing mechanical stability, preserving vascular supply, minimizing soft tissue disruption, and promoting an optimal environment for bone healing by proper decortication and the use of bone graft. The study's findings indicate that the posterior interposition technique, as employed by the SiLO TFX system, removes less bone volume and offers a larger surface area for bony fusion compared to the posterolateral transosseal technique. Specifically, the posterior interposition technique resulted in a 42% +- 8% reduction in mutation/counternutation motion of the sacroiliac joint, outperforming the 14% +- 4% reduction observed with the posterolateral transosSEous technique. Furthermore, upon fatigue loading, the posterior interposition implant maintained the bone-implant interface across all specimens, whereas the posterolateral transos Seous implant inhibited migration or subsidence in 20%-50% of specimens. 공고 • Mar 25
Aurora Spine Corporation Announces FDA 510(K) Clearance for the Aero™? Facet Fusion System Aurora Spine Corporation announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Company's newest product, the AERO™? Facet Fusion System. The AERO MIS Facet Fusion System is a novel, patent-pending device designed to provide a minimally invasive solution for patients suffering from facet joint-related pain or instability. Cleared for use from spinal levels C2 to S1 (inclusive), the system can be used as a stand-alone facet fusion procedure or as an adjunct to larger spinal fusion surgeries. Engineered for earlier use in the continuum of care, AERO is ideal for patients experiencing mechanical back pain, minor instability, or degenerative joint disease who have not responded to conservative therapies. The system incorporates intuitive instrumentation and implant technology designed to promote bone fusion while minimizing soft tissue disruption--aligning with Aurora Spine's commitment to advancing patient-first, surgeon-friendly innovations. Initial surgeries utilizing the AERO system are expected to begin in late Third Quarter 2025, with several leading spine surgeons already selected to participate in an initial clinical study aimed at validating the device's clinical outcomes and long-term benefits. 공고 • Mar 10
Aurora Spine Corporation Announces Completion of Enrollment in Groundbreaking REFINE Study Aurora Spine Corporation announced the completion of patient enrollment in its REFINE study of its ZIP™ Interspinous Fixation device for patients suffering from back pain due to symptomatic degenerative disc disease. This prospective, multi-center, multi-specialty clinical trial is the first of its kind to evaluate the safety and efficacy of lumbar interlaminar fusion devices, marking a significant milestone in the advancement of spinal care. The REFINE study, designed to bridge the gap between conservative treatments and more invasive surgical options, has successfully enrolled its full cohort of patients across multiple centers in the United States. Data from this pioneering study will be published out to one year, with a subsequent cohort publication extending to two years, offering robust, long-term insights into patient outcomes. The results will be presented at the American Society of Pain and Neuroscience (ASPN) annual conference in July 2025, spotlighting Aurora Spine's commitment to evidence-based innovation. Dr. Steven Anagnost, an orthopedic surgeon at Oklahoma Spine and Musculoskeletal Medicine, reflected this optimism: "The impact of the REFINE study cannot be overstated. As an orthopedic surgeon, I see firsthand the need for reliable, minimally invasive solut ions. This trial's comprehensive, multi-specialty approach will shape the future of spinal fusion, offering patients safer and more effective options backed by solid data." Dr. Jason Pope, a pain physician at Evolve Restorative Center in Santa Rosa, CA, highlighted the transformative potential of the study: "True innovation isn't just about new devices, it's about proving they work and delivering real benefits to patients. The REFINE study showcases how Aurora Spine is pushing boundaries, providing hope and tangible improvements for those suffering from debilitating back pain." Aurora Spine's REFINE study stands out for its collaborative design, uniting neurosurgeons, orthopedic surgeons, and interventional pain physicians to assess the ZIP™ MIS Interspinous Fusion System. This minimally invasive technology aims to address unmet needs in treating lumbar spinal stenosis and degenerative disc disease, offering patients a less invasive alternative to traditional spinal surgery. The Company anticipates that the REFINE study's findings will reinforce the efficacy and safety of its ZIP™ system, further solidifying Aurora Spine's position as a trailblazer in the spinal implant market. Aurora Spine remains committed to empowering physicians and improving patient outcomes through groundbreaking clinical evidence and minimally invasive solutions. 공고 • Jan 23
Aurora Spine Corporation Announces the Promotion of Matt Paxton to Executive Vice President of Sales Aurora Spine Corporation announced the promotion of Matt Paxton to Executive Vice President of Sales. As Executive Vice President of Sales, Mr. Paxton will spearhead company-wide initiatives, leveraging his expertise to drive operational excellence and strategic growth. Over the years, Mr. Paxton has demonstrated an unwavering commitment to Aurora Spine’s vision, playing a key role in fostering a culture of collaboration, innovation, and accountability. 공고 • Oct 16
Aurora Spine Corporation Announces Release of Its Hydra Osteo Onyx Lumbar System Aurora Spine Corporation announced it has launched its new OSTEO ONYX™ lumbar fusion system, promoting Rough Surface Technology (RST). The Hydra Osteo Onyx open and MIS systems give Surgeons the opportunity to treat patients who have osteopenia or osteoporosis, as well as their healthier patients. The Osteo Onyx roughened surface technology provides a great purchase within the pedicle that creates a benefit to patients with osteoporosis or poor bone quality. In addition, the range of MIS screws (4.5mm up to 10.5mm) allow its to accommodate any patient with a minimally invasive procedure which leads to better patient recovery and satisfaction. 공고 • May 01
Aurora Spine Corporation to Report Q1, 2024 Results on May 13, 2024 Aurora Spine Corporation announced that they will report Q1, 2024 results on May 13, 2024 공고 • Apr 23
Aurora Spine Corporation, Annual General Meeting, Jun 26, 2024 Aurora Spine Corporation, Annual General Meeting, Jun 26, 2024. 공고 • Jan 18
Aurora Spine Corporation to Showcase Sacroiliac Joint (Si Joint) Fusion Products At North American Neuromodulation Society Annual Meeting Aurora Spine Corporation announced that it will be participating in the North American Neuromodulation Society (NANS) Annual Meeting from January 18-21 in Las Vegas, Nevada. The NANS Annual Meeting is a prominent medical conference that brings together healthcare professionals, researchers, and experts in the field of neuromodulation. Aurora will be showcasing two Sacroiliac Joint (SI Joint) fusion products. Silo TFX and Silo offer physicians options to stabilize the SI Joint, helping patients with access to treatment for their SI joint dysfunction. Aurora Spine will be presenting data from the recent publication of the first 6-month clinical evaluation from the REFINE Screwless™ ZIP™ Study of its ZIP Interspinous Fixation device in the Journal of Pain Research. 공고 • Dec 04
Aurora Spine Corporation Announces Newly Published Paper on First 6-Month Clinical Evaluation of its ZIP™? Fusion Implant Aurora Spine Corporation announced the publication of the first 6-month clinical evaluation of its ZIP™? fusion implant in the Journal of Pain Research. Lumbar interlaminar decompression with interspinous fixation is an established safe and effective treatment for spinal stenosis. Early maintenance of improvements in pain intensity and function are critical for durability of symptom relief. The purpose of this study is to investigate the efficacy of minimally invasive treatments for low back pain during the early period after treatment and their utility in setting the course for longer term success. The scientific paper titled "Early Functional Outcomes in Low Back Pain Subjects with a Novel Interspinous fixation Device: REFINE Study 6-month Results", is a pivotal multi-center study of its ZIP™? InterspinousFixation device for patients suffering from back pain due to symptomatic degenerative disc disease and spinal stenosis. The REFINE Screwless™? ZIP Study utilized patient evaluations at 3- and 6-months following treatment and is part of an actively enrolling, institutional review board (IRB) approved, single-arm, multicenter, prospective, open-label 12-month study. Clinical efficacy was assessed primarily using the change from baseline in Oswestry Disability Index (ODI), Visual Analog Scale (VAS) of the back and leg pain during walking and standing, andurich Claudication Questionnaire (ZCQ), and secondarily using the Patient Global Impression of Change (PGIC) and Patient-Reported Outcomes Measurement Information System (PROMIS). This 6-month interim analysis at 42% enrollment of patients was conducted to determine prolonged safety and efficacy of the ZIP interspinous fusion device. Once in place, the device acts as a fusion support column to open the passageways that contain the spinal cord and nerve roots. This procedure may reduce the compression on the nerves, resulting in potential pain relief in the leg, groin, and buttocks, and then return to a more active lifestyle. 공고 • Oct 24
Aurora Spine Corporation announced that it has received CAD 1.933782 million in funding Aurora Spine Corporation announced a non-brokered private placement to issue 6,445,939 Units at a price of CAD 0.30 per Unit for the gross proceeds of CAD 1,933,781.7 on October 3, 2023. Each Unit is comprised of one common share and one common share purchase warrant of the Company. Each whole warrant is exercisable at a price of CAD 0.50 per common share for a period of 24 months following the date of issuance. In connection with the Offering, the Company paid finder's fees in the amount of CAD 50,700 in the aggregate. The securities issued under the Offering will be subject to a four-month hold period in accordance with applicable securities legislation. The Offering is subject to TSX Venture Exchange final approval. The transaction included participation from certain directors of the Company. 공고 • Sep 14
Aurora Spine Corporation Announces Full Release of its SiLO TFX™? MIS Sacroiliac Joint Fixation System Aurora Spine Corporation announced that it is in full commercial release of its proprietary SiLO TFX™ MIS Sacroiliac Joint Fixation Device system. The patented, minimally invasive SiLO TFX MIS Sacroiliac Joint fixation System is intended for sacroiliac joint disruptions and degenerative sacroiliitis. The SiLO TFX MIS SacROiliac Joint Fixation System includes a Transfixing-Cone, an ilium screw, a sacrum screw and associated instrumentation. The SiLO TFX implants are designed to transfix the sacrum and ilium, providing stability forony fusion. 공고 • Jun 29
Aurora Spine Corporation Announces Initial Patient Enrolled for DEXA-CTM Multicenter Study Aurora Spine Corporation announced that the first patient has been enrolled for its multicenter study of DEXA-CTM Cervical Interbody System. The commencement of the enrollment of patients indicates that the company has received all necessary approvals to launch the study, which will initially include data from 40 single level and 40 multiple level subjects. The DEXA-C system is indicated for anterior cervical interbody fusion procedures and is the first in a series of implants based on Aurora's patented DEXA™? technology platform. Based on the DEXA T-score for measuring a patient's bone density, the DEXA technology platform includes implants that are of varying densities to match a patient's bone density. DEXA-C is intended for use on patients who require anterior cervical discectomy and fusion surgery. The DEX A-C system implants an interbody spacer(s) into the cervical intervertebral body space(s) to stabilize and fuse the level(s). Allograft will be used in the spacer and the spinal segment(s) are fixed with an anterior cervical plate. 공고 • May 24
Aurora Spine Corporation to Report Q1, 2023 Results on May 24, 2023 Aurora Spine Corporation announced that they will report Q1, 2023 results on May 24, 2023 공고 • May 06
Aurora Spine Corporation, Annual General Meeting, Jun 28, 2023 Aurora Spine Corporation, Annual General Meeting, Jun 28, 2023. 
